The possibility for the human transcriptomic machinery to install m 1 A onto the SARS-CoV-2 RNA genome exists. One of the sequence motifs for the m 1 A modification is GUUCRA with R being A or G. An analysis of SARS-CoV-2 genome (NCBI curated reference sequence) found eight such motifs. If all these sites are accessible to the methyltransferases for m 1 A modification, the percentage of adenosines in the genome that can be modified would be 0.089%, which is significantly higher than 0.015-0.054% of adenosines modified in mammalian mRNAs according to a report. With a possibility of installation of m 1 A to the SARS-CoV-2 genome, one would predict that individuals with clinical conditions having increased ability for m 1 A installation would be less likely to be infected by the virus. However, it is well documented that people with cancer, obesity and diabetes are more vulnerable to COVID-19, and these individuals have been reported to have elevated m 1 A modification and the modification has negative effects on prognosis of their clinical conditions. Therefore, their transcriptomic machinery would be more likely to install m 1 A onto the SARS-CoV-2 genome and they would do better for COVID-19 than the general population without considering other factors such as induced immunity. One scenario that can overcome the contradiction could be that m 1 A modification in these individuals are highly dynamic, which is likely. The modification can be installed frequently, and it helps viral survival through mechanisms such as immune evasion, RNA stabilization and translation promotion, but can be removed efficiently for SC2RC to replicate the genome and generate viral mRNAs. Because cancer, obesity and diabetes patients have been reported to have elevated methyltransferases and demethylases, this hypothetical scenario is not impossible.